May 14, 2018 09:17 AM EDT

Troubled aTyr axes 30% of its staff as it wipes a preclinical slate clean

Amber Tong

Faced with disappointing results from its latest preclinical program, aTyr Pharma is cutting the development short and letting go around 30% of its staff. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Troubled aTyr axes 30% of its staff as it wipes a preclinical slate clean

Amber Tong

Sign up to read this article for free.

A look at biotech's year of the megaround

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Regeneron buys London-based ocular biotech

Neumora's major depression drug flunks first of three Phase 3 trials

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Novo petitions FDA over Victoza compounding as first generic wins approval

Trou­bled aTyr ax­es 30% of its staff as it wipes a pre­clin­i­cal slate clean

Amber Tong

Sign up to read this article for free.

more like this

A look at biotech's year of the megaround

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

No­vo pe­ti­tions FDA over Vic­toza com­pound­ing as first gener­ic wins ap­proval

Troubled aTyr axes 30% of its staff as it wipes a preclinical slate clean

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Regeneron buys London-based ocular biotech

Neumora's major depression drug flunks first of three Phase 3 trials

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Novo petitions FDA over Victoza compounding as first generic wins approval